Arcellx Q4 2022 Earnings Report
Key Takeaways
Arcellx reported a successful year with a strategic collaboration with Kite, progress in clinical trials, and scalable manufacturing setup. The company's cash position is $580 million, which will fund operations through BLA filing of CART-ddBCMA planned for the first half of 2025.
Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma.
Presented continued robust long-term responses from CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma.
Enrolled and dosed patients in pivotal iMMagine-1 clinical program for patients with rrMM.
Initiated ACLX-002 for patients with AML/MDS.
Arcellx
Arcellx
Forward Guidance
Arcellx anticipates completing enrollment of iMMagine-1, initiating iMMagine-2 in earlier multiple myeloma lines, and presenting longer-term data from the Phase 1 expansion study of CART-ddBCMA. The company is also beginning commercial planning as it prepares for U.S. market entry.
Positive Outlook
- Completing enrollment of iMMagine-1
- Initiating iMMagine-2 in earlier multiple myeloma lines
- Presenting longer-term data from Phase 1 expansion study of CART-ddBCMA
- Beginning commercial planning
- Preparing for U.S. market entry